Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 0 microdose gemcitabine pharmacokinetic proof-of-concept trial
NL-OMON21758Phase 0Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 0, open-label trial of gemcitabine in non-small cell lung cancer (NSCLC), epithelial ovarian cancer (EOC), pancreatic adenocarcinoma (PDAC) and 3 more, sponsored by Netherlands Cancer Institute. Primary endpoints: Plasma gemcitabine concentration and Pharmacokinetic parameters of gemcitabine. Planned start Mar 2016; status: not yet recruiting.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)epithelial ovarian cancer (EOC)pancreatic adenocarcinoma (PDAC)bladder cancerbreast cancer
Beyond the preview
Go deeper on NL-OMON21758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21758.